Gartner Digital Markets Releases 2024 Global Tech Trends Report at SaaStock Dublin
New survey sheds light on why software buyers experience regret, serving as an essential guide for SaaS providers seeking sustainable growth. DUBLIN–(BUSINESS... Read more.
Crescent European Specialty Lending Announces Financing for the Acquisition of Assisi Pet Care by Wind Point Partners
LONDON & LOS ANGELES–(BUSINESS WIRE)–Crescent Capital Group LP, a leading alternative credit investment firm, announced today that its European Specialty... Read more.
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration... Read more.
AM Best to Sponsor 2023 International Conference on Inclusive Insurance
LONDON–(BUSINESS WIRE)–#insurance—AM Best will sponsor the International Conference on Inclusive Insurance, which will be held 23-27 October 2023... Read more.
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
Not intended for UK-based media ROCKLAND, Mass.–(BUSINESS WIRE)–EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada,... Read more.
KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma
KKR and Flerie to support organic and inorganic growth to extend Coriolis’ leadership position in formulation development and analytical services for innovative... Read more.
Merck to Present Latest Research from Oncology Portfolio at ESMO 2023
Not intended for UK-, US- or Canada-based media DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today announced that... Read more.
Median Technologies’ Global iCRO Team to participate in the 2023 ESMO Congress, Oct 20 – 24, 2023, Madrid, Spain
The iCRO team will be available at Booth #552, Exhibition Hall 5 during the entire industry exhibition duration. Members of the Median Technologies’ team across... Read more.
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
NANTES, France–(BUSINESS WIRE)–Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical... Read more.
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated, Person-Centered... Read more.